盐酸氨溴索和地塞米松对胎鼠肺表面活性蛋白基因表达的影响

目的　探讨盐酸氨溴索和地塞米松对发育期胎鼠肺表面活性蛋白 (SPs)基因表达的影响。方法　将胎鼠 4 2只随机分为生理盐水对照组和盐酸氨溴索、地塞米松两个干预组 ,剖宫取孕19d的胎鼠肺组织作为早产鼠肺模型 ,用原位杂交研究胎鼠肺泡Ⅱ型上皮细胞内SP B基因的表达 ,逆转录PCR(RT PCR)观察分析各组肺表面活性蛋白SP A、SP B和SP CmRNA表达变化 ,用 β actinmRNA扩增产物为内参照密度扫描半定量分析。结果　 (1)发育 19d的胎鼠肺泡Ⅱ型上皮细胞内SP BmRNA表达阳性 ;(2 )鼠胚胎发育后期 ,支气管周围也分布着肺泡Ⅱ型上皮细胞 ;(3)生理盐水对照组SP A、SP B、SP CmRNA表达与 β actinmRNA比值分别为 0 81± 0 2 6、0 97± 0 2 0、0 88± 0 11。盐酸氨溴索干预SP A、SP B、SP CmRNA表达比值分别为 1 0 4± 0 16、1 2 8± 0 2 9、1 0 9± 0 2 5 ,与对照组比较显著性增加 (P <0 0 5 )。地塞米松干预后的胎鼠肺SP A、SP B、SP CmRNA表达比值分别为 1 0 8±0 2 5、1 2 3± 0 35、1 2 1± 0 2 5 ,与对照组比较显著性增加 (P <0 0 5 )。 (4 )对比盐酸氨溴索与地塞米松在促进SP A、SP B、SP C基因表达上 ,两者差异没有显著意义 (P >0 0 5 )。结论　盐酸氨溴索和地塞米松产前用药对发育期的胎鼠SPs基     

Surfactant protein deficiency in familial interstitial lung disease.

OBJECTIVE: To determine the contribution of surfactant protein abnormalities to the development of chronic lung injury in a familial form of interstitial lung disease. STUDY DESIGN: An 11-year-old girl, her sister, and their mother who were diagnosed with chronic interstitial lung disease underwent laboratory investigation of surfactant protein expression in bronchoalveolar lavage fluid and lung biopsy specimens. Nineteen patients with idiopathic pulmonary fibrosis and 9 patients who were investigated for pulmonary malignancy but who did not have interstitial lung disease served as control subjects. RESULTS: The 3 family members were found to have absent surfactant protein C (SP-C) and decreased levels of SP-A and SP-B in bronchoalveolar lavage fluid (BALF). Immunostaining for pulmonary surfactant proteins in lung biopsy specimens obtained from both children demonstrated a marked decrease of pro-SP-C in the alveolar epithelial cells but strong staining for pro-SP-B, SP-B, SP-A, and SP-D. No deviations from published surfactant protein B or C coding sequences were identified by DNA sequence analysis. All control subjects had a detectable level of SP-C in the BALF. CONCLUSION: The apparent absence of SP-C and a decrease in the levels of SP-A and SP-B are associated with familial interstitial lung disease.     

肺复张手法对急性肺损伤幼猪肺表面活性物质的影响

目的 研究肺复张手法(RM)对急性肺损伤(ALI)时肺表面活性物质表达的影响,探讨RM产生肺泡复张效应的机制.方法 健康雄性幼猪12只,静脉注射内毒素(LPS)构建ALI模型,随机分为常规潮气量通气组(对照组)和小潮气量联合肺复张手法通气组(RM组),观察8 h,酶联免疫吸附法检测血浆、支气管肺泡灌洗液(BALF)中的肺表面活性蛋白(SP)-A浓度,分析BALF中的磷脂成分[总磷脂(TPL)、活性磷脂(DSPC)及总蛋白(TP)],并采用RT-PCR和免疫组织化学染色测定肺组织中SP-A、SP-B、SP-C、SP-D的mRNA及SP-A的蛋白表达水平.结果 与对照组相比,RM组中SP-A、SP-B、SP-C、SP-D的mRNA水平明显升高,对照组与RM组SP-A平均灰度值为97.8±6.4与106.3±8.5,差异有非常显著性(P＜0.01),并且采用RM后BALF中DSPC/TP、DSPC/TPL比例升高,血浆中SP-A浓度降低,而BALF中的SP-A浓度明显上升.结论 肺复张手法可以改善ALl幼猪肺表面活性物质相关蛋白的合成及肺部表达,增加肺表面活性物质的活性,调节SP-A的浓度,有助于促进肺复张后的肺泡开放,并减轻呼吸机相关肺损伤.     

Absence of Lamellar Bodies with Accumulation of Dense Bodies Characterizes a Novel Form of Congenital Surfactant Defect

Two female sibling full-term newborns developed respiratory distress shortly after birth, which progressed to respiratory failure. Tracheal lavage demonstrated presence of surfactant protein A (SP-A), but little surfactant protein B (SP-B), without aberrant surfactant protein C (SP-C). On a lung biopsy performed in both infants, prominent type II pneumocyte hyperplasia was evident. Through ultrastructural examination an absence of normally formed lamellar bodies was determined, with numerous irregular electron dense bodies within the type II pneumocytes. These electron dense bodies could also be identified in the alveolar spaces and alveolar macrophages. No alveolar tubular myelin was present. Abnormally high immunoreactivity for surfactant proteins SP-A, proSP-B, SP-B, and proSP-C was demonstrated by light microscopy. Presence of incompletely processed immunopositive proSP-B, but not proSP-C was observed in the alveolar lumina. No mutations in either the SP-B or SP-C gene were identified by sequence analysis of amplified cDNA. We conclude that these siblings exhibit an inherited surfactant deficiency characterized by abnormal accumulations of surfactant proteins within the pneumocytes. This abnormal accumulation may be due to a primary secretory defect, a defect in surfactant phospholipids, or an abnormal interaction between the phospholipids and surfactant proteins. Received November 17, 1998; accepted August 19, 1999.     

Bronchoalveolar lavage surfactant protein a,B, and d concentrations in preterm infants ventilated for respiratory distress syndrome receiving natural and synthetic surfactants

Surfactant proteins (SPs) play an important role in surfactant metabolism and function. Understanding their relative contribution to clinical outcome remains incomplete. Exogenous surfactants differ in their SP content and physiologic effects. The aims of this study were to measure bronchoalveolar lavage (BAL) SP concentrations from preterm infants ventilated for respiratory distress syndrome and to assess their association with clinical outcome. Fifty preterm infants randomized to receive a natural or synthetic surfactant were lavaged each day for the first week and twice weekly thereafter using a standardized nonbronchoscopic technique. BAL SP-A, SP-B, and SP-D concentrations were measured using ELISA. Median BAL SP-A, SP-B, and SP-D concentrations for the whole cohort rose significantly during the first postnatal week (p < 0.05). SP-A concentration did not differ between outcome groups. BAL SP-B concentration rose significantly in lungs that were not supplemented with SP-B. Infants dying had significantly lower BAL SP-B concentrations on d 2 and 6 compared with survivors. BAL SP-D concentrations were significantly lower on d 2 and 3 among infants in supplemental oxygen on d 28 compared with those in air. BAL SP-A and SP-D concentrations did not differ significantly between infants randomized to receive a natural or synthetic surfactant. Lower BAL SP-B and SP-D but not SP-A concentrations were associated with worse clinical prognosis.     

Ontogeny of surfactant apoproteins in the rat

Content of the 26-38-kD surfactant apoprotein (SP-A) was determined in lung homogenates from fetal (17-21 d gestation), postnatal (1-28 d of life), and adult male and female rats by a double sandwich ELISA. Expression of mRNA for SP-A as well as the hydrophobic apoproteins, SP-B and SP-C, were also determined in lung homogenates from fetal and adult rats of both sexes by Northern blot analysis. SP-A was undetectable in fetal lungs on d 17 (day of birth = d 22) and barely detectable on d 18. On d 19 there was a 3- to 4-fold increase in SP-A content above d 18 levels. Between d 19 and 21 SP-A content significantly increased another 6- to 9-fold. SP-A content on the day of birth was not significantly different from that seen on gestational d 21. SP-A content decreased 35-40% between the day of birth and postnatal d 7. After the second postnatal week SP-A content gradually increased, reaching adult levels after d 28. No sex differences in SP-A content were observed during fetal or postnatal lung maturation. SP-A mRNA was first detected in fetal lungs on d 18 and increased in relative abundance until d 21, but remained below adult levels. Developmental changes in fetal lung SP-A content closely paralleled changes in fetal expression of SP-A mRNA. SP-B mRNA was also first detected on d 18, then increased in relative abundance to adult levels by d 20. SP-C mRNA was clearly detectable on d 17, then increased in relative abundance to adult levels by d 20-21. Unlike surfactant phospholipids, there are no apparent sex differences in the expression of any of the surfactant apoproteins during late gestation. The differences observed during fetal lung maturation in the time of onset and changes in relative abundance among the three apoprotein mRNA imply that their genes may be differentially regulated in the developing rat lung.     

Effect of exogenous surfactant on the development of surfactant synthesis in premature rabbit lung

Surfactant replacement is an effective therapy for neonatal respiratory distress syndrome. Full recovery from respiratory distress syndrome requires development of endogenous surfactant synthesis and metabolism. The influence of exogenous surfactant on the development of surfactant synthesis in premature lungs is not known. We hypothesized that different exogenous surfactants have different effects on the development of endogenous surfactant production in the premature lung. We treated organ cultures of d 25 fetal rabbit lung for 3 d with 100 mg/kg body weight of natural rabbit surfactant, Survanta, and Exosurf and measured their effects on the development of surfactant synthesis. Additional experiments tested how these surfactants and Curosurf affected surfactant protein (SP) SP-A, SP-B, and SP-C mRNA expression. Surfactant synthesis was measured as the incorporation of 3H-choline and 14C-glycerol into disaturated phosphatidylcholine recovered from lamellar bodies. Randomized-block ANOVA showed significant differences among treatments for incorporation of both labels (p < 0.01), with natural rabbit surfactant less than control, Survanta greater than control, and Exosurf unchanged. Additional experiments with natural rabbit surfactant alone showed no significant effects in doses up to 1000 mg/kg. Survanta stimulated disaturated phosphatidylcholine synthesis (173 +/- 41% of control; p = 0.01), increased total lamellar body disaturated phosphatidylcholine by 22% (p < 0.05), and increased 14C-disat-PC specific activity by 35% (p < 0.05). The response to Survanta was dose-dependent up to 1000 mg/kg. Survanta did not affect surfactant release. No surfactant altered the expression of mRNA for SP-A, SP-B, or SP-C. We conclude that surfactant replacement therapy can enhance the maturation of surfactant synthesis, but this potential benefit differs with different surfactant preparations.     

Surfactant composition and function in a primate model of infant chronic lung disease: effects of inhaled nitric oxide

Bronchopulmonary dysplasia, or chronic lung disease (CLD), of premature infants involves injury from hyperoxia and mechanical ventilation to an immature lung. We examined surfactant and nitric oxide (NO), which are developmentally deficient in premature infants, in the baboon model of developing CLD. Fetuses were delivered at 125 d gestation and were managed for 14 d with ventilation and oxygen prn without (controls) or with inhaled NO at 5 ppm. Compared with term infants, premature control infants had reduced maximal lung volume, decreased tissue content of surfactant proteins SP-A, -B, and -C, abnormal lavage surfactant as assessed by pulsating bubble surfactometer, and a low concentration of SP-B/phospholipid. NO treatment significantly increased maximal lung volume and tissue SP-A and SP-C, reduced recovery of lavage surfactant by 33%, decreased the total protein:phospholipid ratio of surfactant by 50%, and had no effect on phospholipid composition or SP content except for SP-C (50%). In both treatment groups, levels of SP-B and SP-C in surfactant were negatively correlated with STmin, with a 5-fold greater SP efficiency for NO versus control animals. By contrast, lung volume and compliance were not correlated with surfactant function. We conclude that surfactant is often dysfunctional in developing CLD secondary to SP-B deficiency. NO treatment improves the apparent ability of hydrophobic SP to promote low surface tension, perhaps secondary to less protein inactivation of surfactant, and improves lung volume by a process unrelated to surfactant function.     

High-dose vascular endothelial growth factor increases surfactant protein gene expressions in preterm rat lung

AIMS: To investigate the effects of intra-amniotic vascular endothelial growth factor (VEGF) treatment on surfactant pool sizes and surfactant protein (SP) gene expressions in fetal rat lung. METHOD: On the 18th day of gestation, an abdominal midline incision was performed on timed pregnant Sprague-Dawley rats and the two uterine horns were exposed. VEGF (2.5 microg or 5.0 microg) and saline were injected into the amniotic cavity of the left and right uterine horns, respectively. On the 19th day of gestation, fetuses were delivered by caesarean section. RESULTS: We analyzed the data between the fetuses within the same dam in each group. Mean fetal body weight and lung tissue saturated phosphatidylcholine and total phospholipids were comparable between control and VEGF-treated rats at each VEGF dosage. Lung SP mRNA expressions were comparable between control and VEGF 2.5 microg-treated rats. VEGF 5.0 microg treatment increased lung SP mRNA expressions and the values were statistically significant for SP-B and SP-D mRNAs when compared with the control rats. CONCLUSIONS: These results suggest that VEGF might have potential therapeutic implications in enhancing fetal lung maturation.     

毛细支气管炎患儿血清肺表面活性蛋白A和D的检测及临床意义

目的：探讨血清肺表面活性蛋白A（SP-A）和D（SP-D）在不同程度毛细支气管炎患儿中的变化及其临床意义。方法：将70例毛细支气管炎患儿依据临床症状分为毛细支气管炎急性期组（42例）和恢复期组（28例）,另选取26例同期因非感染性疾病住院的小儿外科术前患儿为对照组;同时依据症状严重程度将急性期毛细支气管炎患儿分为重症组（12例）和轻症组（30例）。采用竞争性ELISA法定量测定各组血清SP-A和SP-D水平变化。结果：毛细支气管炎急性期组患儿血清SP-A和SP-D水平显著高于恢复期组和对照组（均P<0.01）,且恢复期组与对照组比较,血清SP-A和SP-D仍维持在较高水平（P<0.01）;重症组患儿血清SP-A和SP-D水平明显高于轻症组（P<0.01）。结论：毛细支气管炎患儿急性期血清SP-A和SP-D水平明显增高,且随病情加重而增高;临床症状缓解后,血清SP-A和SP-D水平仍然维持在较高水平。     

Surfactant protein A and D gene polymorphisms and protein expression in victims of sudden infant death

Aim: To investigate the innate immune components surfactant protein A (SP-A) and D (SP-D) in victims of sudden infant death syndrome (SIDS).
Methods: Ten common single nucleotide polymorphisms (SNPs) in the exons of SP-A1, SP-A2 and SP-D genes were analysed in 42 cases of SIDS and 46 explained sudden infant deaths. SP-A and SP-D protein expression in tissue from the aerodigestive tract was semi-quantitatively evaluated by immunohistochemistry.
Results: SP-D immunoreactivity was found in lungs and tissue from submandibular gland, palatine tonsils and duodenum. Positive SP-A immune staining was found exclusively in lung tissue. Neither the allele nor the haplotype distribution of the SP-A and SP-D genes was significantly different in SIDS compared to explained deaths. The most common SP-A haplotype, 6A2/1A0, tended to be overrepresented in the cases with low immunohistochemical SP-A expression (61%) compared to cases with high expression (49%), p = 0.08. The SP-D expression was not influenced by the 11 C/T or 160 A/G polymorphisms.
Conclusion: No significant association between the common genetic variants of SP-A and SP-D and SIDS is disclosed by the present study. However, low SP-A protein expression may possibly be determined by the 6A2/1A0 SP-A haplotype, this should be subject for further investigation.     

LOCALIZATION AND FUNCTIONS OF SP-A AND SP-D AT MUCOSAL SURFACES

Pulmonary surfactant protein A (SP-A) and D (SP-D), members of the collectin family, are implicated in innate host defense of the lung. Collectins consist of a collagen-like domain and a carbohydrate recognition domain. SP-A and SP-D recognize and interact with glycoconjugates on the surface of microorganisms. They protect the lung by interacting with a wide variety of potential pathogens, including viruses, bacteria, and fungi. This may result in enhanced killing and/or clearance by phagocytes. Although most extensively studied in the lung, both SP-A and SP-D, or proteins closely resembling SP-A and SPD, are found in a number of other sites in the body and therefore may play a protective role at other sites than the lung. SP-A and SP-D protein and/or mRNA have been detected at various sites of the body: the respiratory tract, the gastrointestinal tract, the middle ear, and in the peritoneal cavity. The presence of SP-A and SP-D at these mucosal surfaces, in close contact with numerous potentially harmful microorganisms, supports a role for these "lung"-collectins in innate mucosal defense. SP-A and SP-D may be important molecules in a threefold innate defense, particularly in the neonatal period between maternally acquired immunity and a fully developed adaptive immune system; the time interval between first exposure to a pathogen and generation of specific antibodies; and states of impaired immune function.     

LIPID-PROTEIN INTERACTIONS OF HYDROPHOBIC PROTEINS SP-B AND SP-C IN LUNG SURFACTANT ASSEMBLY AND DYNAMICS

Phospholipids have the major role in pulmonary surfactant concerning its biophysical function of reducing surface tension at the alveolar air-liquid interface to facilitate respiratory mechanics. However, the presence of some specific, highly hydrophobic polypeptides is essential to modulate the physical behavior of phospholipids and to promote rapid formation of stable surface films that are able to produce surface tensions in the range of 0 dynes/cm during cyclic compression. The present review summarizes the available data on the parameters governing lipid-protein interactions of the hydrophobic surfactant proteins SP-B and SP-C with the main surfactant phospholipids. Lipid-protein interactions in surfactant have been studied in vitro using preparations reconstituted with very different methodological procedures. Conclusions concerning the role of hydrophobic surfactant proteins on the assembly of lipid-protein surfactant structures in vivo have been revised in this respect. This review presents the knowledge available on the disposition of SP-B and SP-C in surfactant structures, the mode, extent, selectivity, and stoichiometry of their lipid-protein interactions, and the effect of the proteins on structure and dynamics of surfactant bilayers and monolayers. Some considerations are given to possible concerted actions, under physiological conditions, of both proteins SP-B and SP-C.     

FUNCTIONAL MAPPING OF SURFACTANT PROTEIN A

Surfactant protein A (SP-A) is a highly ordered, oligomeric glycoprotein that is secreted into the airspaces of the lung by alveolar type II cells and Clara cells of the pulmonary epithelium. Although research has shown that SP-A is both a calcium-dependent phospholipid-binding protein that affects surfactant structure and function and a lectin that opsonizes diverse microbial species, our understanding of the physiologically relevant roles of SP-A in the lung remains incomplete. My review focuses on the putative biological functions of SP-A that are supported by experiments in mammals and on the structural basis of SP-A function.     

Leptin enhances lung maturity in the fetal rat

Pulmonary alveolar type II cells synthesize and secrete phospholipids and surfactant proteins. In most mammalian species, the synthesis of phospholipids and proteins of lung surfactant increases with fetal lung maturation, which occurs late in gestation. Factors that may promote lung maturation and surfactant production include the placental hormone, leptin, whose expression increases with advancing gestational age. We demonstrate that physiologic concentrations of leptin (1 and 10 ng/mL) increase the levels of surfactant proteins (SP) A, B, and C mRNA as well as SP-A and SP-B protein in d-17 fetal rat lung explants in vitro. To determine whether leptin exerts similar effects in vivo, we administered leptin antenatally to pregnant rats and compared its effects to that of dexamethasone, a known mediator of fetal lung development. Antenatal treatment with leptin for 2 d significantly increased the average weight of the fetal lungs in relation to their body weight. Histologic analysis revealed that the increase in fetal lung weight was accompanied by an increase in the number and maturation of type II alveolar cells and the expression of surfactant proteins B and C in these cells. Collectively, these results suggest that leptin is a cytokine regulator of rat fetal lung maturity.     

Alveolar epithelial cell differentiation and surfactant protein expression after mild preterm birth in sheep

As the transition to extrauterine life at birth alters the proportions of type I and II alveolar epithelial cells (AECs), our aim was to determine the effect of mild preterm birth on AECs and surfactant protein (SP) gene expression. Preterm lambs were born at approximately 133 d of gestational age (DGA); controls were born at term (approximately 147 DGA). Lungs were collected from preterm lambs at term-equivalent age (TEA; approximately 2 wk after preterm birth) and 6 wk post-TEA. Control lung tissue was collected from fetuses (at 132 DGA), as well as from lambs at approximately 6 h (normal term) and 2, 6, and 8 wk of postnatal age (PNA). In controls, the proportion of type I AECs decreased from 65.1 +/- 3.9% at term to 50.9 +/- 3.3%, while the proportion of type II AECs increased from 33.7 +/- 3.9% to 48.5 +/- 3.3% at 6 wk PNA. At 2 wk after preterm birth, the proportions of type I and II AECs were similar in preterm lambs compared to 132-d fetal levels and term controls but differed from control values at 2 wk PNA; differences between control and preterm lambs persisted at 8 wk PNA. At approximately 2 wk after preterm birth, SP-A and SP-B, but not SP-C, mRNA levels were significantly reduced in preterm lambs compared with term controls, but these differences did not persist at 2 and 6 wk PNA. We conclude that mild preterm birth alters the normal postnatal changes in type I and II cell proportions but does not severely affect SP gene expression.     

CONGENITAL ALVEOLAR PROTEINOSIS IN THE NETHERLANDS: A Report of Five Cases with Immunohistochemical and Genetic Studies on Surfactant Apoproteins

Congenital alveolar proteinosis is a recently described cause of lung dysfunction and respiratory distress in term neonates. In several cases a deficiency or insufficiency of surfactant apoprotein B SP-B has been caused by a frameshift mutation in the gene encoding SP-B. Five full-term children in three unrelated families from The Netherlands are reported. Immunohistochemistry demonstrated large amounts of surfactant proteins A and C SP-A and SP-C and precursors in alveolar cells and in intra-alveolar material. Results were positive for antibovine SP-B antibody but negative for antipig SP-B1 antibody, most probably reflecting differences in the antibody specificity. The findings suggest abnormal SP-B function. In two sibs, no pre-SP-C was demonstrated in the alveoli, although it was found in considerable amounts in alveolar cells. One such case has previously been reported. In two families, the parents were heterozygous for the 121 ins 2 mutation in the SP-B gene. Our findings suggest that congenital alveolar proteinosis may result from abnormalities in one or more of the surfactant proteins.